Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reproductive immunology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Reproductive immunology. Displaying page 1 of 1.
    EudraCT Number: 2018-000105-23 Sponsor Protocol Number: DYDRA001 Start Date*: 2019-03-01
    Sponsor Name:UZ Brussel
    Full Title: Oral dydrogesterone (OD) versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in IVF/ICSI: pharmacokinetics and the impact on the endometrium, the microbiota of the genital t...
    Medical condition: Female infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023185-42 Sponsor Protocol Number: S105AMCNilotinibSpA Start Date*: 2011-04-21
    Sponsor Name:Academic Medical Center, Division of Clinical Immunology and Rheumatology
    Full Title: Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis
    Medical condition: Active axial and peripheral spondyloarthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010955-29 Sponsor Protocol Number: 10031983 Start Date*: 2009-07-13
    Sponsor Name:Division of Clinically Immunology and Rheumatology, AMC
    Full Title: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
    Medical condition: Pre-clinical RA patients with a high risk on developing the disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000786-24 Sponsor Protocol Number: NET-2013-02355002 Start Date*: 2017-03-07
    Sponsor Name:IRCCS Burlo Garofolo
    Full Title: Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000614-64 Sponsor Protocol Number: VIRUSNET201401 Start Date*: 2015-12-17
    Sponsor Name:Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University
    Full Title: Study of recombinant adenovirus in patients with neuroendocrine neoplasms; safety and efficacy
    Medical condition: Neuroendocrine neoplasms (NENs) is a heterogeneous group with varying symptoms, tumor biology and treatment response. NENs may occur in any organ, most commonly they are observed in the gastroente...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001416-30 Sponsor Protocol Number: IDH2-Post-Allo-Trial Start Date*: 2020-06-18
    Sponsor Name:Heinrich-Heine-University Düsseldorf represented by the Coordinating Investigator
    Full Title: IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation
    Medical condition: Patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or acute myelogenous leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) and with an IDH2 mutat...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024329 Leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 11:24:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA